Rockefeller Capital Management L.P. Acquires Shares of 18,186 Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Rockefeller Capital Management L.P. acquired a new stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 18,186 shares of the company’s stock, valued at approximately $205,000. Rockefeller Capital Management L.P. owned about 0.25% of Global X Genomics & Biotechnology ETF as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Centaurus Financial Inc. raised its holdings in shares of Global X Genomics & Biotechnology ETF by 7.0% during the third quarter. Centaurus Financial Inc. now owns 14,996 shares of the company’s stock valued at $169,000 after acquiring an additional 985 shares in the last quarter. Atria Investments Inc bought a new position in shares of Global X Genomics & Biotechnology ETF during the third quarter valued at approximately $122,000. Corrado Advisors LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 3.0% during the third quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock valued at $723,000 after acquiring an additional 1,894 shares in the last quarter. James J. Burns & Company LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 6.0% during the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock valued at $207,000 after acquiring an additional 1,038 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new position in shares of Global X Genomics & Biotechnology ETF during the second quarter valued at approximately $590,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Stock Down 1.2 %

Shares of Global X Genomics & Biotechnology ETF stock opened at $10.65 on Thursday. The company has a market cap of $77.86 million, a PE ratio of -4.55 and a beta of 1.03. The business has a 50 day moving average of $10.62 and a 200 day moving average of $10.85. Global X Genomics & Biotechnology ETF has a 52 week low of $9.52 and a 52 week high of $12.53.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.